Indian pharma is in a transformative phase following the pricing pressure on generic drugs in its key market, the US. While most firms are making a transition to less competitive complex generics and speciality drugs, Wockhardt is going beyond with its novel-drugs pipeline of five antibiotics.
Habil Khorakiwala, chairman of Wockhardt, is playing David vs Goliath to get a share of the blockbuster drugs market in the US, so far dominated by multinational giants. Only 11 antibiotics in clinical trials have received qualified infectious disease product (QIDP) status from the US FDA, ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Sun, January 21 2018. 23:48 IST
